IPO

With a top Hong Kong director and stars on the NBA stage and Disney+, Catwalk Entertainment is building a content empire to take Mandarin media global.

Fermi America's plan to revive nuclear power for AI's energy needs with a massive Texas campus faces past industry failures and new legal scrutiny.

The firm behind a controversial drug-permissive sporting event is hitting Wall Street via a SPAC, challenging the ethics of global anti-doping standards.

Cohen & Co.-backed SPAC joins the hunt for a merger target, highlighting a renewed investor appetite for blank check companies in a maturing market.

With revolutionary tech and a volatile stock, PureCycle's year-end update is a critical test of its operational progress and financial promises.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

F/m Investments just launched a fund that's both an ETF and a mutual fund. Here's why this regulatory first is a game-changer for the entire industry.

VisionWave Holdings is leveraging a breakthrough in non-line-of-sight detection to compete for a piece of the Pentagon's new $13.4 billion autonomy budget.

Due to massive investor demand, Western Copper and Gold upsized its financing to C$80M, fueling the critical next steps for its giant Casino copper-gold project.

A mid-market bank's AI deal reveals a larger trend: how specialized financiers are becoming the crucial, unseen engine behind tech's next evolution.

Datasea's profits are booming despite a revenue drop, as it pivots to high-margin AI and futuristic acoustic tech. Is this a genius move or a risky gamble?

Granted a 180-day extension, the APAC entertainment firm battles a low stock price despite revenue growth and strategic pivots in a booming market.

A 37-year-old patient receives a successful heart transplant at UCSF after being sustained by a SynCardia Total Artificial Heart, a major clinical win.

With $255M from star investors, a firm is betting on a radical idea: that treating employees with dignity is the best way to generate returns.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

A new plant-derived drug shows promise in preventing prostate cancer and improving cholesterol, but the company faces significant financial hurdles ahead.

The iconic brand is pivoting from its print legacy to a diversified lifestyle empire, and it has a new plan to convince investors it's the right move.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

Gilat DataPath will supply advanced, combat-proven SATCOM terminals to a European MoD, marking a key expansion in the region's push for digital sovereignty.

Crypto giants BitGo and 21shares expand their global partnership, building regulated infrastructure to meet surging institutional demand for digital assets.